0001140361-16-087797.txt : 20161123
0001140361-16-087797.hdr.sgml : 20161123
20161123172411
ACCESSION NUMBER: 0001140361-16-087797
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161121
FILED AS OF DATE: 20161123
DATE AS OF CHANGE: 20161123
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTEOSTASIS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001445283
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-225-0096
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEOSTASIS THERAPEUTICS INC
DATE OF NAME CHANGE: 20080916
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cormorant Global Healthcare Master Fund, LP
CENTRAL INDEX KEY: 0001618442
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 162017341
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-848-3429
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cormorant Global Healthcare GP, LLC
CENTRAL INDEX KEY: 0001618451
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 162017342
BUSINESS ADDRESS:
STREET 1: 100 HIGH STREET
STREET 2: SUITE 1105
CITY: BOSTON
STATE: DC
ZIP: 02110
BUSINESS PHONE: 617-848-3429
MAIL ADDRESS:
STREET 1: 100 HIGH STREET
STREET 2: SUITE 1105
CITY: BOSTON
STATE: DC
ZIP: 02110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chen Bihua
CENTRAL INDEX KEY: 0001599214
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 162017343
MAIL ADDRESS:
STREET 1: C/O CORMORANT ASSET MANAGEMENT, LLC
STREET 2: 200 CLARENDON STREET, 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cormorant Asset Management, LLC
CENTRAL INDEX KEY: 0001583977
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37695
FILM NUMBER: 162017344
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-702-0388
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
STREET 2: 52ND FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
doc1.xml
FORM 4
X0306
4
2016-11-21
0
0001445283
PROTEOSTASIS THERAPEUTICS, INC.
PTI
0001583977
Cormorant Asset Management, LLC
200 CLARENDON STREET, 52ND FLOOR
BOSTON
MA
02116
0
0
1
0
0001599214
Chen Bihua
C/O CORMORANT ASSET MANAGEMENT, LLC
200 CLARENDON STREET, 52ND FLOOR
BOSTON
MA
02116
1
0
1
0
0001618451
Cormorant Global Healthcare GP, LLC
200 CLARENDON STREET, 52ND FLOOR
BOSTON
MA
02116
0
0
1
0
0001618442
Cormorant Global Healthcare Master Fund, LP
200 CLARENDON STREET, 52ND FLOOR
BOSTON
MA
02116
0
0
1
0
Common Stock
2016-11-21
4
P
0
111863
11.6448
A
3129945
I
See Footnotes
Common Stock
2016-11-22
4
P
0
69500
11.0765
A
3199445
I
See Footnotes
Common Stock
2016-11-23
4
P
0
180300
11.372
A
3379745
I
See Footnotes
Common Stock
2016-11-23
4
P
0
200
10.67
A
3379945
I
See Footnotes
Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of the Master Fund and the Account. Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant and GP LLC. GP LLC may be deemed to beneficially own the shares held by the Master Fund, and Cormorant and Ms. Chen may be deemed to beneficially own the shares held by the Master Fund and the Account.
Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.325 to $11.75 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 93,014 were purchased for the Master Fund and 18,849 shares were purchased for the Account. As of November 21, 2016, the Master Fund held 2,609,501 shares, and the Account held 520,444 shares.
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $10.72 to $11.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 57,790 were purchased for the Master Fund and 11,710 shares were purchased for the Account. As of November 22, 2016, the Master Fund held 2,667,291 shares, and the Account held 532,154 shares.
Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $10.96 to $11.75 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 149,919 were purchased for the Master Fund and 30,381 shares were purchased for the Account.
Of these shares, 166 were purchased for the Master Fund and 34 shares were purchased for the Account. As of November 23, 2016, the Master Fund held 2,817,376 shares, and the Account held 562,569 shares.
/s/ CORMORANT GLOBAL HEALTHCARE GP, LLC By: Bihua Chen, Managing Member
2016-11-23
/s/ CORMORANT ASSET MANAGEMENT, LLC By: Bihua Chen, Managing Member
2016-11-23
/s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member
2016-11-23
/s/ Bihua Chen
2016-11-23